CIP29 Activators
CIP29 activators encompass a diverse range of compounds that engage with and amplify the functional activity of CIP29 through various biochemical pathways. Forskolin, for instance, enhances the cAMP-dependent pathway crucial to CIP29's role in RNA processing, facilitating CIP29's nuclear translocation and activity. Similarly, IBMX elevates cAMP levels, bolstering CIP29's functionality within the same signaling cascade. The involvement of protein kinase C in CIP29's activity is augmented by PMA, which can increase CIP29's involvement in mRNA export through PKC-induced phosphorylation changes. Ionomycin, adding another layer, heightens intracellular calcium and, through calcium-dependent kinases, can indirectly augment CIP29's role in spliceosomal processes. The epigenetic landscape influencing CIP29 is modulated by compounds like Epigallocatechin gallate, which by inhibiting DNA methyltransferases, may enhance CIP29's engagement in mRNA processing.
Trichostatin A, an HDAC inhibitor, potentially expands CIP29's activity by altering chromatin structure and thus the expression of proteins within the CIP29-mediated pathways, enhancing CIP29's role in mRNA splicing. Inhibitors like 5-Azacytidine and ZM447439 target DNA methylation and Aurora kinases respectively, both of which may lead to an upregulation of CIP29 activity by impacting gene expression or phosphorylation states of proteins within its pathways. Similarly, PD98059 and LY294002, by inhibiting MEK and PI3K respectively, may redirect signaling cascades in a manner that indirectly upregulates CIP29's role in pre-mRNA processing and mRNA transport. Rapamycin's inhibition of mTOR can lead to enhanced autophagic activity that may degrade proteins inhibiting CIP29, thereby potentially increasing CIP29's activity in RNA transportation. Lastly, staurosporine's broad kinase inhibition could have a multitude of effects, potentially enhancing the interaction of CIP29 with other proteins in RNA processing pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, increasing cAMP levels, which can enhance the activity of CIP29 by promoting the cAMP-dependent signaling pathway, thereby fostering the nuclear translocation and function of CIP29 in RNA processing. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-specific inhibitor of phosphodiesterases, leading to an accumulation of cAMP. Elevated cAMP levels can subsequently enhance CIP29 activity by reinforcing the cAMP-dependent signaling cascade that CIP29 is part of. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC) which can modulate the phosphorylation status of proteins within the signaling pathways that CIP29 is involved in, potentially increasing CIP29's activity in mRNA export. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels, which may indirectly enhance CIP29 activity by calcium-dependent protein kinase pathways, affecting CIP29's role in the spliceosome. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit DNA methyltransferases, which could lead to the hypomethylation of the promoter regions of genes encoding proteins that interact with CIP29, thus enhancing CIP29's functional activity in mRNA processing. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA is an inhibitor of histone deacetylase (HDAC), which can result in a more relaxed chromatin structure and potentially increased expression of proteins within the CIP29-mediated pathways, enhancing CIP29's role in mRNA splicing. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a DNA methyltransferase inhibitor, 5-Azacytidine can induce demethylation and reactivate silenced genes, possibly leading to the upregulation of proteins that interact with or regulate CIP29, enhancing its activity in mRNA metabolism. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM447439 is an Aurora kinase inhibitor, and by inhibiting Aurora kinases, it could alter the phosphorylation state of downstream targets that modulate the pathways CIP29 is involved in, potentially enhancing the protein's activity in RNA binding. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, which could lead to the upregulation of alternate pathways that involve CIP29, thus indirectly enhancing its activity in pre-mRNA processing. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can indirectly enhance CIP29 activity by affecting the AKT signaling pathway and leading to the modulation of proteins that govern the transport and processing of mRNA, in which CIP29 is a key player. | ||||||